• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

炎症性肠病中的硫嘌呤:新发现与新视角。

Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives.

机构信息

Department of Gastroenterology and Hepatology, VU University Medical Centre, Amsterdam, The Netherlands.

Department of Gastroenterology and Hepatology and Inserm U954, Nancy University Hospital, Lorraine University, Vandoeuvre-lès-Nancy, France.

出版信息

J Crohns Colitis. 2018 Apr 27;12(5):610-620. doi: 10.1093/ecco-jcc/jjx181.

DOI:10.1093/ecco-jcc/jjx181
PMID:29293971
Abstract

Thiopurines, available as azathioprine, mercaptopurine, and thioguanine, are immunomodulating agents primarily used to maintain corticosteroid-free remission in patients with inflammatory bowel disease. To provide a state-of-the-art overview of thiopurine treatment in inflammatory bowel disease, this clinical review critically summarises the available literature, as assessed by several experts in the field of thiopurine treatment and research in inflammatory bowel disease.

摘要

硫嘌呤类药物有硫唑嘌呤、巯嘌呤和硫鸟嘌呤,是免疫调节剂,主要用于维持炎症性肠病患者的皮质类固醇激素缓解。为了提供炎症性肠病中硫嘌呤治疗的最新概述,本临床综述批判性地总结了该领域的几位专家评估的现有文献,以及炎症性肠病中硫嘌呤治疗和研究的专家。

相似文献

1
Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives.炎症性肠病中的硫嘌呤:新发现与新视角。
J Crohns Colitis. 2018 Apr 27;12(5):610-620. doi: 10.1093/ecco-jcc/jjx181.
2
The Thiopurine Tale: An Unexpected Journey.硫唑嘌呤的故事:一段意想不到的旅程。
J Crohns Colitis. 2022 Aug 4;16(7):1177-1183. doi: 10.1093/ecco-jcc/jjac004.
3
Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety.硫唑嘌呤、6-巯基嘌呤在炎症性肠病中的应用:药理学、疗效及安全性
Clin Gastroenterol Hepatol. 2004 Sep;2(9):731-43. doi: 10.1016/s1542-3565(04)00344-1.
4
Optimizing treatment with thioguanine derivatives in inflammatory bowel disease.优化硫鸟嘌呤衍生物在炎症性肠病中的治疗
Best Pract Res Clin Gastroenterol. 2003 Feb;17(1):37-46. doi: 10.1053/bega.2002.0346.
5
Indicators of clinical response to treatment with six-mercaptopurine or azathioprine in patients with inflammatory bowel disease.炎症性肠病患者对6-巯基嘌呤或硫唑嘌呤治疗的临床反应指标
Inflamm Bowel Dis. 2004 Jul;10(4):339-45. doi: 10.1097/00054725-200407000-00003.
6
A practical guide to the use of thiopurines in oral medicine.口腔医学中硫嘌呤类药物使用实用指南。
J Oral Pathol Med. 2015 Nov;44(10):761-8. doi: 10.1111/jop.12274. Epub 2014 Dec 19.
7
Thioguanine Therapy in Inflammatory Bowel Diseases. A Practical Guide.巯嘌呤在炎症性肠病中的治疗。实用指南。
J Gastrointestin Liver Dis. 2020 Dec 13;29(4):637-645. doi: 10.15403/jgld-2765.
8
Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease.综述文章:药物遗传学在改善炎症性肠病硫嘌呤治疗中的益处。
Aliment Pharmacol Ther. 2012 Jan;35(1):15-36. doi: 10.1111/j.1365-2036.2011.04905.x. Epub 2011 Nov 2.
9
Thiopurine Metabolism in the Era of Combotherapy.联合治疗时代的硫嘌呤代谢
Inflamm Bowel Dis. 2016 Jun;22(6):1496-501. doi: 10.1097/MIB.0000000000000737.
10
Erythrocyte mean corpuscular volume as a surrogate marker for 6-thioguanine nucleotide concentration monitoring in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine.红细胞平均体积作为炎症性肠病患者接受硫唑嘌呤或6-巯基嘌呤治疗时6-硫鸟嘌呤核苷酸浓度监测的替代标志物。
Inflamm Bowel Dis. 2003 Jul;9(4):237-45. doi: 10.1097/00054725-200307000-00004.

引用本文的文献

1
Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis.硫唑嘌呤和6-巯基嘌呤用于维持溃疡性结肠炎缓解
Cochrane Database Syst Rev. 2025 Feb 27;2(2):CD000478. doi: 10.1002/14651858.CD000478.pub5.
2
Early Ustekinumab Use Improves Clinical Outcomes in Biologic-Naive Crohn's Disease Patients: A Retrospective Multicenter Cohort Study in Taiwan.早期使用优特克单抗可改善初治克罗恩病患者的临床结局:台湾一项回顾性多中心队列研究
Biomedicines. 2025 Feb 6;13(2):391. doi: 10.3390/biomedicines13020391.
3
Chemotherapeutic 6-thio-2'-deoxyguanosine selectively targets and inhibits telomerase by inducing a non-productive telomere-bound telomerase complex.
化疗药物6-硫代-2'-脱氧鸟苷通过诱导一种无活性的端粒结合端粒酶复合物,选择性地靶向并抑制端粒酶。
bioRxiv. 2025 Feb 19:2025.02.05.636339. doi: 10.1101/2025.02.05.636339.
4
Worldwide research trends in Crohn's disease treatment over the past 2 decades: a bibliometric analysis.过去20年全球克罗恩病治疗的研究趋势:一项文献计量分析
Front Pharmacol. 2024 Oct 8;15:1441785. doi: 10.3389/fphar.2024.1441785. eCollection 2024.
5
Cost-effectiveness and cost-utility of optimized mercaptopurine treatment versus placebo in ulcerative colitis patients: The randomized controlled OPTIC trial.优化巯嘌呤治疗与安慰剂在溃疡性结肠炎患者中的成本效益和成本效用:随机对照 OPTIC 试验。
United European Gastroenterol J. 2024 Nov;12(9):1256-1265. doi: 10.1002/ueg2.12661. Epub 2024 Oct 13.
6
Quantification of deoxythioguanosine in human DNA with LC-MS/MS, a marker for thiopurine therapy optimisation.采用 LC-MS/MS 定量检测人 DNA 中的脱氧硫代鸟苷,这是优化巯嘌呤治疗的标志物。
Anal Bioanal Chem. 2024 Dec;416(29):6711-6723. doi: 10.1007/s00216-024-05581-6. Epub 2024 Oct 13.
7
Artificial intelligence and machine learning technologies in ulcerative colitis.溃疡性结肠炎中的人工智能和机器学习技术
Therap Adv Gastroenterol. 2024 Sep 5;17:17562848241272001. doi: 10.1177/17562848241272001. eCollection 2024.
8
Management of Crohn's disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023.台湾地区克罗恩病的管理:2023年更新的台湾炎症性肠病学会共识指南
Intest Res. 2024 Jul;22(3):250-285. doi: 10.5217/ir.2024.00060. Epub 2024 Jul 29.
9
Innovating Thiopurine Therapeutic Drug Monitoring: A Systematic Review and Meta-Analysis on DNA-Thioguanine Nucleotides (DNA-TG) as an Inclusive Biomarker in Thiopurine Therapy.创新硫嘌呤治疗药物监测:以 DNA-硫鸟嘌呤核苷酸 (DNA-TG) 为包容性生物标志物的硫嘌呤治疗的系统评价和荟萃分析。
Clin Pharmacokinet. 2024 Aug;63(8):1089-1109. doi: 10.1007/s40262-024-01393-0. Epub 2024 Jul 20.
10
Diagnosis and Pharmacological Management of Microscopic Colitis in Geriatric Care.老年医学中小肠结肠炎的诊断和药物治疗管理。
Drugs Aging. 2024 Feb;41(2):113-123. doi: 10.1007/s40266-023-01094-6. Epub 2024 Jan 17.